Exploring the Profiles of ROS1 Tyrosine Kinase: A Structural Analysis of G2032R and D2033N Mutations
- PMID: 40336761
- PMCID: PMC12054649
- DOI: 10.4103/ijabmr.ijabmr_43_24
Exploring the Profiles of ROS1 Tyrosine Kinase: A Structural Analysis of G2032R and D2033N Mutations
Abstract
Background: ROS1, a proto-oncogene, drives cancer through chromosomal fusions. The G2032R and D2033N mutations, common in ROS1-rearranged non-small cell lung cancer, hinder crizotinib treatment. We investigate these mutations' impact on ROS1 structure through molecular dynamics (MD) simulations, revealing destabilization. Our findings shed light on how these mutations contribute to cancer development.
Materials and methods: The crystal structure of human ROS1 (PDB ID: 7z5x) served as the template for homology modeling and further mutation insertion of G2032R and D2033N substitutions introduced using Swiss-PdbViewer. The MD simulations were conducted on the wild-type (WT) and mutant ROS1 kinase domains to explore the structural changes and interactions.
Results: The initial model of the human ROS1 crystal structure was constructed, incorporating missing loop residues and then utilized for the MD simulation studies. The examination of conformational changes in WT, G2032R, and D2033N mutant ROS1 proteins involved observing alterations in the C-alpha protein. We observed that the mutations resulted in deviations in the MD trajectory over the 500 ns period. Consequently, the MD simulations unveiled significant conformational changes induced by the G2032R and D2033N mutations, affecting protein stability and dynamics, particularly in regions such as the ATP binding and active sites.
Conclusion: Our study constructed an initial model of the human ROS1 and used it for MD simulation studies to examine the conformational changes in ROS1 mutants. Notably, our observations revealed that the mutations caused deviations in the MD trajectory. The G2032R and D2033N mutations significantly alter ROS1 structure, affecting its stability and dynamics, offering key insights into their role in cancer disease development.
Keywords: Molecular dynamics simulation; ROS1; mutation G2032R D2033N; non-small cell lung cancer.
Copyright: © 2025 International Journal of Applied and Basic Medical Research.
Conflict of interest statement
There are no conflicts of interest.
Figures







Similar articles
-
Investigation on the binding mechanism of loratinib with the c-ros oncogene 1 (ROS1) receptor tyrosine kinase via molecular dynamics simulation and binding free energy calculations.J Biomol Struct Dyn. 2018 Sep;36(12):3106-3113. doi: 10.1080/07391102.2017.1378127. Epub 2017 Sep 25. J Biomol Struct Dyn. 2018. PMID: 28893136
-
Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion-Positive Lung Cancer.Clin Cancer Res. 2021 May 15;27(10):2899-2909. doi: 10.1158/1078-0432.CCR-21-0032. Epub 2021 Mar 8. Clin Cancer Res. 2021. PMID: 33685866 Free PMC article.
-
Gaining insight into crizotinib resistance mechanisms caused by L2026M and G2032R mutations in ROS1 via molecular dynamics simulations and free-energy calculations.J Mol Model. 2017 Apr;23(4):141. doi: 10.1007/s00894-017-3314-z. Epub 2017 Mar 30. J Mol Model. 2017. PMID: 28361443
-
Comprehensive Review of ROS1 Tyrosine Kinase Inhibitors-Classified by Structural Designs and Mutation Spectrum (Solvent Front Mutation [G2032R] and Central β-Sheet 6 [Cβ6] Mutation [L2086F]).J Thorac Oncol. 2024 May;19(5):706-718. doi: 10.1016/j.jtho.2023.12.008. Epub 2023 Dec 7. J Thorac Oncol. 2024. PMID: 38070596 Review.
-
Targeting ROS1 Rearrangements in Non-small Cell Lung Cancer: Crizotinib and Newer Generation Tyrosine Kinase Inhibitors.Drugs. 2019 Aug;79(12):1277-1286. doi: 10.1007/s40265-019-01164-3. Drugs. 2019. PMID: 31313100 Review.
References
-
- Kenzerki ME, Ahmadi M, Mousavi P, Ghafouri-Fard S. MYC and non-small cell lung cancer: A comprehensive review. Human Gene. 2023;37:201185.
-
- Gridelli C, Rossi A, Carbone DP, Guarize J, Karachaliou N, Mok T, et al. Non-small-cell lung cancer. Nat Rev Dis Primers. 2015;1:15009. - PubMed
-
- Duma N, Santana-Davila R, Molina JR. Non-small cell lung cancer: Epidemiology, screening, diagnosis, and treatment. Mayo Clin Proc. 2019;94:1623–40. - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous